Intellia Raises $180M with 16.7M Shares at $10.75
Intellia Therapeutics is conducting a public offering of 16,744,187 shares at $10.75 each to raise approximately $180 million before expenses, with a 30-day option for underwriters to purchase an additional 2,511,628 shares. Proceeds will bolster the company’s cash position to advance its CRISPR gene-editing pipeline.
1. Offering Details
Intellia Therapeutics announced an underwritten public offering of 16,744,187 common shares at $10.75 per share, targeting gross proceeds of approximately $180 million before underwriting discounts and expenses.
2. Underwriting Terms
Jefferies, Goldman Sachs and Citigroup are serving as joint book-running managers and have a 30-day option to purchase up to 2,511,628 additional shares at the same public offering price less underwriting discounts and commissions.
3. Strategic Implications
The capital infusion is intended to strengthen Intellia’s balance sheet and extend cash runway, supporting ongoing and planned clinical programs in its CRISPR gene-editing pipeline and broader research initiatives.